HPS-094 - Real-world impact of finerenone on renal function in Type 2 Diabetes-Related Chronic Kidney Disease

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-094
• By: LIN, Yu Wen (Cheng Hsin General Hospital, Taiwan)
• Co-author(s): Mrs Yu Wen Lin (Cheng Hsin General Hospital, Taipei, Taiwan / Taipei Pharmacists Association, Taipei, Taiwan)
  Mr Shang Feng Yang (Cheng Hsin General Hospital, Taipei, Taiwan)
  Mrs Hung Chuan Chang (Cheng Hsin General Hospital, Taipei, Taiwan / Taipei Pharmacists Association, Taipei, Taiwan)
  
• Abstract:

  Introduction
  Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, was approved in Taiwan on July 1, 2022, for adults with type 2 diabetes-related chronic kidney disease (CKD). It reduces the risk of CKD progression, ESRD, cardiovascular events, and heart failure hospitalizations. Based on the FIDELIO-DKD and FIGARO-DKD..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login